- Pre-exposure chemoprophylaxis involves the use of antiretroviral drugs taken daily by individuals who are HIV negative to protect themselves from the infection

- Current data indicates that when taken as prescribed, pre-exposure chemoprophylaxis profoundly reduces the risk of HIV infection

- Pre-exposure chemoprophylaxis has been shown to be cost-effective in individuals at high risk for HIV infection. Besides the United States, it is used in Europe, Brazil, Australia, Uganda, Kenya, and South Africa

- Pre-exposure chemoprophylaxis offers no protection against other sexually transmitted infections

- Pre-exposure chemoprophylaxis for prevention of HIV must be delivered as part of a comprehensive package that deals with STD prevention

- The effectiveness of pre-exposure chemoprophylaxis drops significantly if the individual has poor adherence with medication use